Ipsen BioPharm Ltd
⚠️ High Risk
FEI: 1000346340 • Wrexham, Clwyd • UNITED KINGDOM
FEI Number
1000346340
Location
Wrexham, Clwyd
Country
UNITED KINGDOMAddress
Unit 9, Ash Road North, Wrexham, Clwyd, United Kingdom
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NO LICENSE
The article is subject to refusal of admission under section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because it appears to be a biological product for which a biologics license is not in effect under the Public Health Service Act, Part F, Subpart 1-Biological Products, Section 351(a), and it is not the subject of an Investigational New Drug application that is in effect. Therefore, it appears to be a new drug under 201(p) of the FD&C Act that it is in violation of section 505(a) of the FD&C Act because it lacks a new drug approval and because it is misbranded under section 502(f)(1)of the FD&C Act because it fails to bear adequate directions for use
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
DRUG GMPS
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B).
NEW VET DR
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it appears to be a new animal drug that is unsafe within the meaning of Section 512(a) of the Federal Food, Drug, and Cosmetic Act as it is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing, and no investigational new animal drug exemption applies.
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 4/15/2025 | 58PCY05ONABOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/12/2024 | 63NDK23ACETYLCHOLINE CHLORIDE (CHOLINERGIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/8/2023 | 58PCK01ABOBOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/3/2023 | 58PCK01ABOBOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/14/2022 | 65QCY02BOTOX | Division of Southeast Imports (DSEI) | |
| 12/13/2022 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/2/2022 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/6/2022 | 65QAY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/3/2018 | 65QCP02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/12/2018 | 65QCY02BOTOX | Division of Southeast Imports (DSEI) | |
| 3/6/2018 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 2/28/2018 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 2/28/2018 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 12/7/2016 | 65QCK02BOTOX | 75UNAPPROVED | Division of Northern Border Imports (DNBI) |
| 9/7/2016 | 65QDY02BOTOX | 71NO LICENSE | Division of Southeast Imports (DSEI) |
| 11/23/2015 | 65QCP02BOTOX | Cincinnati District Office (CIN-DO) | |
| 3/6/2008 | 65JCA24NORETHINDRONE (PROGESTIN) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 10/18/2007 | 62CCY99ANTI-HYPERTENSIVE N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 10/18/2007 | 62CCY99ANTI-HYPERTENSIVE N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 1/21/2005 | 62ZCK06ARSENIC TRIOXIDE (ANTI-NEOPLASTIC - PART II) | New York District Office (NYK-DO) | |
| 10/20/2004 | 61PRY17INSULIN (INJ) (ANTI-DIABETIC) | 72NEW VET DR | New York District Office (NYK-DO) |
| 11/24/2002 | 66VCP99MISCELLANEOUS PATENT MEDICINES, ETC. | 71NO LICENSE | New Orleans District Office (NOL-DO) |
Frequently Asked Questions
What is Ipsen BioPharm Ltd's FDA import refusal history?
Ipsen BioPharm Ltd (FEI: 1000346340) has 22 FDA import refusal record(s) in our database, spanning from 11/24/2002 to 4/15/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Ipsen BioPharm Ltd's FEI number is 1000346340.
What types of violations has Ipsen BioPharm Ltd received?
Ipsen BioPharm Ltd has been cited for 8 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Ipsen BioPharm Ltd come from?
All FDA import refusal data for Ipsen BioPharm Ltd is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.